Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurocrine Biosciences
Marketing
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space
Launches from companies including Boehringer and Bristol Myers could drive sales of schizophrenia drugs up to $17 billion by 2031.
Nick Paul Taylor
Dec 19, 2024 9:17am
FDA approves Neurocrine's Crenessity for genetic adrenal disease
Dec 16, 2024 11:26am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
Neurocrine joins in on Tardive Dyskinesia Awareness Week
May 6, 2024 10:52am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
Neurocrine asks ‘What the C@H?!’ in new hyperplasia campaign
Apr 25, 2024 12:04pm